Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Reliq Health Technologies Inc V.RHT.H

Alternate Symbol(s):  RQHTF

Reliq Health Technologies Inc. is a global healthcare technology company that specializes in developing virtual care solutions for the healthcare market. The Company’s iUGO Care platform supports care coordination and community-based virtual healthcare. iUGO Care allows complex patients to receive care at home, improving health outcomes, enhancing quality of life for patients and families and... see more

TSXV:RHT.H - Post Discussion

Reliq Health Technologies Inc > Fundamentals - Part 2
View:
Post by theinvestor22 on Mar 03, 2023 9:32am

Fundamentals - Part 2

On Feb 11th, I posted something on the company's price/revenue multiple to show how it was declining over a period of time, meaning that the stock price was becoming cheaper.  I thought it might be a good idea to update my posting now that fQ2 results have been issued.

First, the guts of my original posting...

(Note: for the following, I've used the price on the day of each earnings release, the revenue as supplied by the company in a couple of MD&As, annualized quarterly results and the basic share count.)
 
When Q1 f2021 results were announced, the price/revenue multiple was about $0.265 stock price / ($170k rev x 4 Qs / 143,119 sh) = 55.8
 
When Q1 f2022 results were announced, the price/revenue multiple was about $1.25 stock price / ($1,608k rev x 4 Qs / 176,634 sh) = 34.3
 
When Q1 f2023 results were announced, the price/revenue multiple was about $0.69 stock price / ($3,472k rev x 4 Qs / 189,356 sh) = 9.4
 
Since the price is currently $0.51, the current price/revenue multiple is about $0.51 stock price / ($3,472k rev x 4 Qs / 189,356 sh) = 7.0


Now, to add something for the latest results...

When Q2 f2023 results were announced, the price/revenue multiple was about $0.54 stock price / ($4,119k rev x 4 Qs / 195,759 sh) = 6.4

So, it seems the stock price is becoming even more reasonable.
Comment by lscfa on Mar 03, 2023 10:16am
Co. needs to triple revenues to get to its 45% ebitda margin goal....   Patients 55,500 Revenue @ $50/mo 33,300,000 Gross profit 24,975,000 Gross margin 75% Cash expenses (10,000,000)  ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities